Search the Newsreel

AxoGen (NASDAQ:AXGN) EVP Marc Began Sells 67,500 Shares of Stock

AxoGen EVP Marc Began sold 67,500 shares of company stock for approximately $3.20 million, reducing his direct holdings by over 57%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, AxoGen shares rose, nearing their 52-week high, and …

AxoGen (NASDAQ:AXGN) Director Sells $646,552.26 in Stock

AxoGen Director Amy McBride Wendell sold 13,353 shares of AXGN stock for over $646,000, reducing her total holdings by 11.01%. This sale occurred under a pre-arranged Rule 10b5-1 plan, and comes as AxoGen shares traded up 2.5% to $49.67, near their 52-week high, following …

Axogen Insider Sold Shares Worth $3,195,788, According to a Recent SEC Filing

An insider at Axogen (AXGN) sold shares valued at $3,195,788, as disclosed in a recent SEC filing. This transaction follows another reported insider sale of $646,592 on the same day. Axogen specializes in technologies for peripheral nerve regeneration and repair.

Axogen, Inc. SEC Filing (Aug 11, 2026)

This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 11, 2026, detailing a proposed sale of 13,353 common shares with an aggregate market value of $643,881.66 through Morgan Stanley Smith Barney LLC. The securities were acquired on the …

Axogen (AXGN) Is Up 5.4% After Raising 2026 Revenue Outlook Despite Ongoing Losses – Has The Bull Case Changed?

Axogen (AXGN) reported higher Q2 2026 revenue of US$69.73 million but increased net losses of US$1.52 million. Despite ongoing losses, the company raised its full-year 2026 revenue outlook to at least US$279 million, leading to a 5.4% stock increase. This updated guidance reinforces the …

Axogen stock hits 52-week high at 47.09 USD By Investing.com

Axogen Inc. (AXGN) stock reached a new 52-week high of $47.09, trading at $47.11 with a market capitalization of $2.52 billion, representing a 231.91% surge over the past year. InvestingPro analysis indicates the stock is currently overvalued, yet net income is projected to grow, …

Is Axogen (AXGN) Still Below Fair Value As Strong Q2 Results Lift Guidance?

AxoGen Inc (AXGN) Stock News Today

This article provides an overview of AxoGen Inc (AXGN) stock, including its current price, market capitalization, and a note that more

Axogen, Inc. SEC Filing (Aug 7, 2026)

This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 7, 2026. The filing indicates a proposed sale of 14,150 shares with an aggregate market value of $627,552.50, acquired through Restricted Stock Units on June 19, 2026. The filing …

AxoGen Number of Employees 2026 | Employee Count & Headcount Data

AxoGen (NASDAQ: AXGN) has 652 employees globally as of March 2026, marking a 36.7% growth since 2023. The company is actively hiring with 57 job postings in 2026, and its workforce is primarily concentrated in North America. Despite growth, overall employee sentiment is negative …

HC Wainwright Predicts AxoGen's Q1 Earnings (NASDAQ:AXGN)

Why Axogen (AXGN) Is Up 6.9% After Raising 2026 Revenue Guidance Despite First-Half Loss

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel (NASDAQ:AXGN)

Axogen is evolving from a specialized tissue supplier into a comprehensive nerve care platform, driven by FDA approval, improved reimbursement, and growing clinical evidence. The company reported strong Q2 2026 revenue growth of 23.1% to $69.7M, raising full-year guidance, though gross margin saw a …

Axogen, Inc. Stock 12‑Month Price Target Raised to $51.33, Implies 25% Upside

The average 12-month price target for Axogen, Inc. (AXGN) stock has been raised by analysts from $50.78 to $51.33, representing a potential upside of approximately 25% from its July 28 closing price. This new target is based on estimates from 9 analysts, with individual …

Vanguard Capital Management (AXGN) discloses 4.99% Axogen Inc ownership on Schedule 13G/A

Vanguard Capital Management LLC and its affiliated entities have reported a 4.99% beneficial ownership stake in Axogen Inc, according to an amended Schedule 13G filing. This ownership amounts to 2,654,445 shares of common stock, with Vanguard exercising sole voting power over 396,497 shares and …

Axogen (AXGN) Stock Faces Margin Squeeze Despite Strong Revenue Growth

Axogen (AXGN) reported strong Q2 2026 revenue growth of US$69.7m, yet its stock slipped slightly due to a net loss of US$1.5m and a dip in gross margin to 72.7%. While breast neurotization programs are driving revenue, higher-cost grafts are squeezing profitability, challenging the …

H.C. Wainwright raises AxoGen stock price target to $53 on guidance

H.C. Wainwright raised its price target on AxoGen (NASDAQ: AXGN) to $53 from $50, maintaining a Buy rating, following strong second-quarter 2026 financial results where revenue exceeded projections. The company also increased its 2026 revenue guidance. Despite the positive analyst sentiment and impressive stock …

Axogen, Inc. 2Q 2026: Revenue $69.73M, EPS ($0.03) — 10-Q Summary

Axogen, Inc. reported its second-quarter 2026 results, showing a 23.1% year-over-year revenue increase to $69.73 million. Despite the revenue growth, the company posted a GAAP net loss of ($1.52M) and diluted EPS of ($0.03), compared to a net income in the prior year. Key …

Axogen (AXGN) Is Up 5.1% After Raising 2026 Outlook On Breast Reconstruction Surge - Has The Bull Case Changed?

Axogen, Inc. (NASDAQ: AXGN) grows revenue 24.7% and retires debt

Axogen, Inc. reported strong revenue growth for the first half of 2026, with a 24.7% increase year-over-year to $131.188 million, driven by higher unit volumes and pricing. Despite this growth, the company posted a net loss of $21.1 million for the six-month period, primarily …

AxoGen: Q2 Earnings Snapshot

This article provides a snapshot of AxoGen's Q2 earnings. No specific financial details are available in the provided content, but it indicates a focus on their financial performance for the quarter.

Press Release: Axogen, Inc. Reports Second Quarter 2026 Financial Results

Axogen, Inc. has announced its financial results for the second quarter of 2026. The company reported a significant increase in revenue, driven by strong growth in its nerve repair product portfolio. Axogen also updated its full-year guidance, projecting continued expansion.

Axogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Axogen, Inc. announced its earnings results for the second quarter and first six months of 2026. For Q2 2026, sales increased to $69.

Axogen Inc earnings missed by $0.24, revenue topped estimates

Axogen Inc (NASDAQ: AXGN) reported second-quarter earnings per

Axogen, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AXGN) 2026-07-29

Axogen, Inc. (AXGN) published its Q2 2026 earnings call presentation on July 29, 2026. The company reported an EPS of $0.12, which beat estimates by $0.00, and revenue of $69.73 million, representing a 23.06% year-over-year increase and beating estimates by $2.64 million. The slide …

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

Trace Biosciences has received a strategic investment from Axogen, the global leader in surgical peripheral nerve function solutions. This investment is part of Trace's Series A financing and will support the clinical development of Nerve Trace, a near-infrared fluorescence imaging technology designed to visualize …

Nerve Trace imaging begins Phase I trial with Axogen backing

Trace Biosciences announced a strategic investment from Axogen (NASDAQ: AXGN) as part of its Series A financing to advance clinical development of its Nerve Trace near-infrared fluorescence imaging technology. Nerve Trace Dx, the lead candidate, has begun a Phase I trial after receiving FDA …

AxoGen (NASDAQ:AXGN) Issues Earnings Results, Misses Expectations By $0.15 EPS

AxoGen Q2 Earnings Call Highlights

Axogen Inc (AXGN) reported a 23% year-over-year revenue growth in Q2 2026, driven significantly by the breast market, and increased its full-year revenue guidance. Despite this strong growth and robust financial health with $113.4 million in cash, the company experienced a decrease in gross …

How Axogen Inc. (AXGN) Affects Rotational Strategy Timing

Axogen Inc. (NASDAQ: AXGN) is showing divergent sentiment across all horizons, suggesting choppy conditions with a mid-channel oscillation pattern. The article presents institutional trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, highlighting a significant 44.4:1 risk-reward …

Axogen earnings on deck as nerve repair reimbursement gains gather steam

Axogen Inc. is set to report its second-quarter earnings, with analysts expecting revenue growth driven by recent reimbursement changes for nerve repair procedures. Investors will be closely watching if the new CMS outpatient reimbursement reclassification, which took effect in January 2026, is leading to …

AxoGen Inc (AXGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of AxoGen Inc (AXGN), noting its current valuation score is 8.49, ranking 91 out of 199 in its industry. The company's P/E ratio stands at -64.71, significantly below its recent high and above its recent low. Key valuation …

234,495 Shares in AxoGen, Inc. $AXGN Acquired by SummitTX Capital L.P.

SummitTX Capital L.P. recently acquired 234,495 shares of AxoGen, Inc. (NASDAQ:AXGN) totaling approximately $7.8 million, now owning 0.44% of the company. Institutional investors collectively hold 80.29% of AxoGen's stock, and while analysts generally rate it a "Moderate Buy" with an average target price of …